The Standing Doctrine as Exit Ramp: What the Court's Mifepristone Ruling Actually Preserved

The Official Narrative

In June 2024, the Supreme Court ruled unanimously in FDA v. Alliance for Hippocratic Medicine that anti-abortion physicians and medical organizations lacked standing to challenge the Food and Drug Administration's regulatory decisions expanding access to mifepristone, a medication used in over half of all abortions in the United States. The decision preserved the status quo: mifepristone remains available by mail without an in-person doctor visit, approved for use through ten weeks of pregnancy.

The framing from the Court's majority, authored by Justice Brett Kavanaugh, emphasized procedural neutrality. The plaintiffs had not demonstrated a concrete injury sufficient to confer Article III standing. They were not required to prescribe or participate in abortions, and their objections were rooted in moral opposition rather than personal harm. The Court did not address whether the FDA's approval process was lawful or whether mifepristone's expanded availability posed safety concerns.

Justices Clarence Thomas and Samuel Alito dissented—not from the outcome, but from the Court's refusal to consider whether other plaintiffs might have standing. Their position: the case should not have been dismissed without identifying whether any party could bring the challenge. This dissent was widely interpreted as a signal that the conservative justices remain prepared to revisit abortion access through pharmaceutical regulation, even after Dobbs v. Jackson Women's Health Organization returned the issue to the states.

The headline narrative: the Court preserved abortion pill access. The structural question: what did it actually preserve, and from what?

The Constitutional Mechanism: Article III Standing

Article III, Section 2 of the Constitution limits federal judicial power to "Cases" and "Controversies." The Supreme Court has interpreted this to require that plaintiffs demonstrate: (1) a concrete and particularized injury, (2) fairly traceable to the defendant's conduct, and (3) likely to be redressed by a favorable decision. This is the doctrine of standing—a procedural threshold that determines who may invoke federal court jurisdiction, not what the law requires.

The standing doctrine has been a cornerstone of judicial restraint since Lujan v. Defenders of Wildlife (1992), which held that generalized grievances shared by the public at large do not confer standing. The plaintiff must show a personal stake in the outcome. In Alliance for Hippocratic Medicine, the physicians argued they faced indirect injury: they might be required to treat patients experiencing complications from mifepristone abortions. The Court found this speculative and too attenuated to satisfy Article III.

This is not a novel application. In Clapper v. Amnesty International (2013), the Court rejected standing for plaintiffs who could not demonstrate that their communications were actually surveilled, only that surveillance was possible. The injury must be "actual or imminent," not "conjectural or hypothetical."

The Gap: What Was Not Decided

The gap between the Court's procedural dismissal and the public framing of "preserved access" is structurally significant. The Court did not rule that the FDA's approval of mifepristone was lawful. It did not affirm the agency's authority to expand access via telemedicine or mail delivery. It did not address whether the FDA followed proper procedures under the Administrative Procedure Act. It did not evaluate the safety data. It did not adjudicate whether the Comstock Act—an 1873 law criminalizing the mailing of abortion-related materials—applies to mifepristone.

Justice Kavanaugh's majority opinion explicitly noted that the decision "does not resolve the merits" and that "other plaintiffs" with standing could bring future challenges. The Court left open the door for states, which have "sovereign interests" in regulating medical practice and public health, to sue. Indeed, in a footnote, the opinion acknowledged that three states—Idaho, Kansas, and Missouri—had filed a separate lawsuit in the Fifth Circuit raising similar claims. That case was not before the Court in 2024.

The Alito-Thomas dissent underscored this gap. Alito wrote that the Court should have addressed whether Idaho or other states had standing, rather than dismissing the case and leaving the question unresolved. His dissent did not argue that the plaintiffs before the Court had standing—it argued that the Court should have done more work to identify who could sue. This is procedural maneuvering framed as judicial duty.

What the Gap Reveals

The strategic use of standing doctrine here reveals two structural realities. First, the Court is not uniformly enforcing standing requirements. In cases involving environmental regulation, immigration, and election law, the Court has both tightened and loosened standing depending on the underlying merits. In Biden v. Nebraska (2023), the Court found that Missouri had standing to challenge student loan forgiveness based on speculative injury to a state loan servicer's revenue. In United States v. Texas (2023), the Court held that Texas lacked standing to challenge immigration enforcement priorities. The doctrine is wielded inconsistently.

Second, the absence of merits review in Alliance for Hippocratic Medicine does not reflect judicial restraint—it reflects deferral. The substantive debate over mifepristone's regulatory status has been postponed, not resolved. The Court punted. The Alito-Thomas dissent is a roadmap: find the right plaintiff, and the case returns.

This is not a competence failure. It is a deliberate institutional strategy. The Court avoided a direct ruling on abortion pill access less than two years after Dobbs, at a moment of intense public scrutiny and political volatility. The standing dismissal allowed the Court to appear procedurally neutral while preserving the option to revisit the issue once litigation from state plaintiffs matures.

What Structural Accountability Looks Like

The mechanism for accountability here is transparency about what was not decided. The Court did not validate the FDA's actions. It did not foreclose future challenges. It applied a procedural rule that it has applied selectively in other contexts. The public deserves clarity about the difference between a procedural dismissal and a merits ruling.

If the Court's application of standing doctrine is inconsistent, that inconsistency should be named and scrutinized. If the dissent by Alito and Thomas signals intent to revisit the issue with a different plaintiff, that intent should be understood as part of the decision's operative meaning. The formal outcome—"case dismissed"—obscures the functional outcome: the substantive fight over mifepristone's availability is unresolved and ongoing.

The trajectory of this case depends on whether the public and the press distinguish between what the Court said and what it left unsaid. The official narrative of "preserved access" assumes the issue is settled. The structural record shows it is not.